The biotech sector continues to be a hotbed of innovation, with companies under $10 billion capturing attention for their breakthrough therapies and rapid growth potential.
These fastest-growing biotech stocks are not only advancing cutting-edge treatments but are also backed by strong insurer coverage and expanding international interest, signaling robust revenue streams and long-term scalability.
Here are 9 of the top fastest-growing biotech stocks under $10 billion, featuring strong insurer support and rising international demand.
| Company Name (Ticker) | Analyst Upside | P/E Ratio |
| Arcutis Biotherapeutics (ARQT) | 26.4% | -107.41 |
| Tarsus Pharmaceuticals (TARS) | 54% | -275.90 |
| Crinetics Pharmaceuticals (CRNX) | 124.4% | -5.85 |
| Palvella Therapeutics (PVLA) | 22.3% | -16.71 |
| IO Biotech (IOBT) | 408.5% | -1.81 |
| Spero Therapeutics (SPRO) | 168.8% | -1.11 |
| Vir Biotechnology (VIR) | 302.4% | -1.49 |
| Tiziana Life Sciences Ltd (TLSA) | 314.4% | -10.72 |
| BridgeBio Pharma, Inc. (BBIO) | 24.3% | -21.29 |
Unlock our Free Report: 5 undervalued compounders with upside based on Wall Street’s growth estimates that could deliver market-beating returns (Sign up for TIKR, it’s free) >>>
The 3 biotech stocks below stand out for their rapid revenue growth, strong insurer coverage, and expanding international reach, positioning them as high-potential opportunities.
Arcutis Biotherapeutics (ARQT)
Arcutis Biotherapeutics stands out among sub-$10 billion biotechs with growth rates that far outpace many of its peers. The company is building a leadership position in dermatology by addressing common but underserved conditions such as psoriasis, eczema, and atopic dermatitis. Unlike many clinical-stage biotechs, Arcutis has already demonstrated commercial success, reporting a 164% year-over-year revenue increase in Q2 2025. This growth reflects both strong physician adoption and patient demand, highlighting the company’s ability to translate innovative science into a scalable business model.
For investors, the appeal lies in Arcutis’s disciplined focus on areas with high unmet need, which not only accelerates development timelines but also provides meaningful pricing power and market exclusivity. The company’s premium-priced therapies and efficient commercialization strategy are fueling robust revenue expansion, while partnerships and licensing agreements broaden its market presence and reduce execution risk. With a market capitalization still well under $10 billion, Arcutis represents a rare blend of rapid top-line growth, operational discipline, and a clear therapeutic focus. This positions the company as one of the most compelling high-growth biotech opportunities with significant long-term upside potential.
Value any stock in under 30 seconds with TIKR’s new Valuation Model (it’s free) >>>
Tarsus Pharmaceuticals (TARS)
Tarsus Pharmaceuticals has carved a niche in ophthalmic and infectious disease therapies, targeting conditions with limited treatment options.Its strategic focus on underserved ophthalmology markets has allowed it to achieve impressive adoption rates for its therapies. Q2 2025 sales surged by 152% year-over-year to $102.7 million, highlighting strong revenue growth and operational scalability.
By concentrating on diseases with high unmet need, Tarsus can command favorable pricing and build a loyal patient base. The company’s growth is further amplified by its late-stage pipeline, which includes promising drug candidates that expand its addressable market. Precision formulation technologies and targeted delivery systems give Tarsus a competitive edge, improving both efficacy and patient outcomes.
This focus on innovation, combined with strong commercial execution, has positioned Tarsus as a fast-growing player in the biotech sector. Under $10 billion in market capitalization, Tarsus represents the ideal profile for a high-growth biotech: a company leveraging innovation to penetrate specialized markets while scaling revenue rapidly. Its disciplined execution, coupled with an expanding pipeline, ensures it remains a compelling growth story in the ophthalmology-focused biotech space.
Find stocks that we like even better than Tarsus Pharmaceuticals today with TIKR (It’s free) >>>
Crinetics Pharmaceuticals (CRNX)
Crinetics Pharmaceuticals stands out for its focus on rare endocrine and metabolic disorders, an area of biotech that combines high unmet medical need with strong market potential. The company has successfully advanced multiple clinical-stage programs, including its lead candidate, paltusotine for acromegaly, which has received FDA acceptance for New Drug Application review. This progress demonstrates Crinetics’ ability to efficiently translate scientific innovation into commercially promising therapies.
What makes Crinetics particularly compelling is its operational discipline and capital efficiency. The company has advanced a diverse pipeline without overextending resources. Its focus on rare diseases also allows for accelerated regulatory pathways, giving Crinetics the potential to bring therapies to market faster than traditional large-cap biotech companies.
With strong near-term catalysts from upcoming clinical data and potential market approvals, Crinetics exemplifies a fast-growing biotech company under $10 billion. Its combination of innovative, high-impact science, financial prudence, and strategic focus on rare diseases ensures it remains a standout investment opportunity in the rapidly evolving biotech sector.
Value stocks like Crinetics Pharmaceuticals quicker with TIKR >>>
Wall Street Analysts Are Bullish on These 5 Undervalued Compounders With Market-Beating Potential
TIKR just released a new free report on 5 compounders that appear undervalued, have beaten the market in the past, and could continue to outperform on a 1-5 year timeline based on analysts’ estimates.
Inside, you’ll get a breakdown of 5 high-quality businesses with:
- Strong revenue growth and durable competitive advantages
- Attractive valuations based on forward earnings and expected earnings growth
- Long-term upside potential backed by analyst forecasts and TIKR’s valuation models
These are the kinds of stocks that can deliver massive long-term returns, especially if you catch them while they’re still trading at a discount.
Whether you’re a long-term investor or just looking for great businesses trading below fair value, this report will help you zero in on high-upside opportunities.
Click here to sign up for TIKR and get our full report on 5 undervalued compounders completely free.
Looking for New Opportunities?
- See what stocks billionaire investors are buying so you can follow the smart money.
- Analyze stocks in as little as 5 minutes with TIKR’s all-in-one, easy-to-use platform.
- The more rocks you overturn… the more opportunities you’ll uncover. Search 100K+ global stocks, global top investor holdings, and more with TIKR.
Disclaimer:
Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any stocks mentioned. Thank you for reading, and happy investing!
